公开(公告)号：US4483849A

公开(公告)日：1984-11-20

申请号：US430755

申请日：1983-01-07

申请人： William A. Carter ,  Gerald Silver

发明人： William A. Carter ,  Gerald Silver

IPC分类号： C07K14/565 ,  A61K45/02 ,  C07G7/00

CPC分类号： C07K14/565

摘要： A new process for stabilizing purified human interferon is described, using propylene glycol. Propylene glycol also aids in the interferon purification procedure. Older methods used stabilizing agents which are toxic, antigenic or irritating. The new process will make available significantly more interferon of clinical purity for use in patients with cancer, viral illnesses and other diseases as yet undesignated (e.g. multiple sclerosis, amyotropic lateral sclerosis, scleroderma, etc.).

摘要翻译： 使用丙二醇描述了稳定纯化的人类干扰素的新方法。 丙二醇也有助于干扰素纯化程序。 较老的方法使用有毒，抗原或刺激的稳定剂。 新方法将使癌症，病毒性疾病和其他疾病患者（例如多发性硬化，脊髓性侧索硬化，硬皮病等）中临床纯度的干扰素明显增加。

公开(公告)号：US5958718A

公开(公告)日：1999-09-28

申请号：US905957

申请日：1997-08-05

申请人： William A. Carter

发明人： William A. Carter

IPC分类号： A61K31/70 ,  A61K31/195 ,  A61K31/713 ,  A61K39/39 ,  A61K48/00 ,  A61K49/00 ,  A61P25/02 ,  A61P25/28 ,  A61P37/04 ,  C07H21/00 ,  C07H21/02 ,  C12Q1/25 ,  C12Q1/34 ,  C12Q1/68 ,  G01N20060101 ,  G01N33/483 ,  G01N33/49 ,  G01N33/50 ,  G01N33/53 ,  G01N33/573 ,  G01N33/68 ,  C12N9/22

CPC分类号： A61K31/70 ,  G01N33/6896 ,  G01N2333/922 ,  G01N2800/2814

摘要： The presence of neuro-cognitive disorders associated with systemic immunological malfunction are assessed in human patients by determining the level of intracellular RNase L in a sample of the patient's peripheral blood and comparing that level to predetermined levels of RNase L in healthy individuals. Aberrant RNase L levels as compared with those in healthy individuals indicate the presence of neuro-cognitive disorders associated with systemic immunological malfunction. This procedure is useful to distinguish systemic immunological malfunction from primary psychological or neuropsychiatric disorders presenting otherwise similar clinical symptoms.

摘要翻译： 通过测定患者外周血样品中的细胞内RNA酶L的水平，并将该水平与健康个体中的RNA酶L的水平进行比较，在人类患者中评估与全身免疫功能障碍相关的神经认知障碍的存在。 与健康个体相比，异常核糖核酸酶L水平表明与全身免疫功能障碍相关的神经认知障碍的存在。 该程序可用于将系统性免疫功能障碍与原发性心理或神经精神障碍相区别，其中出现相似的临床症状。

公开(公告)号：US5683986A

公开(公告)日：1997-11-04

申请号：US384396

申请日：1995-02-03

申请人： William A. Carter

发明人： William A. Carter

IPC分类号： A61K31/785 ,  A61K31/80 ,  A61K48/00 ,  C07H21/02

CPC分类号： A61K31/713

摘要： Parenterally administered systemic dsRNAs release host mediators into various compartmentalized biological fluids to combat various microorganisms, particularly viruses, thereby reducing the infectivity and spread of various organisms including those associated with various diseases such as those caused by venereal warts, herpes and HIV.

摘要翻译： 非肠道给药的系统性dsRNA将宿主介体释放到各种分隔的生物流体中以对抗各种微生物，特别是病毒，从而降低各种生物体的感染性和扩散，包括与诸如由性病，疱疹和HIV引起的各种疾病相关的生物体。

公开(公告)号：US5593973A

公开(公告)日：1997-01-14

申请号：US318514

申请日：1994-10-05

申请人： William A. Carter

发明人： William A. Carter

IPC分类号： C07C41/03 ,  C07C67/08 ,  C07C69/58 ,  C07H21/00 ,  C12Q1/70 ,  A61K31/70 ,  C12Q1/68

CPC分类号： A61K31/70 ,  C07H21/00 ,  C12Q1/701

摘要： Hepatitis viral infections are efficaciously treated with mismatched dsRNAs, notably rI.sub.n.r(C.sub.11-14,U).sub.n.

摘要翻译： 肝炎病毒感染通过不匹配的dsRNA有效治疗，特别是rIn.r（C11-14，U）n。

公开(公告)号：US5132292A

公开(公告)日：1992-07-21

申请号：US528962

申请日：1990-05-25

申请人： William A. Carter

发明人： William A. Carter

IPC分类号： A61K31/70 ,  A61K31/522 ,  A61K31/662 ,  A61K31/7048 ,  A61K31/713 ,  A61K38/04 ,  A61K49/00 ,  A61P1/16 ,  A61P31/12 ,  A61P31/20 ,  A61P43/00 ,  C07H21/02 ,  C12Q1/25 ,  C12Q1/70 ,  G01N33/576

CPC分类号： A61K31/70 ,  A61K38/04 ,  A61K49/0004

摘要： Hepatitis viral infections are efficaciously treated with mismatched dsRNAs, notably rI.multidot.r(C.sub.11-14,.sup.U).sub.n, alone or in combination with one or more of ganciclovir, coumermycin Al, dideoxyinosine or its nucleoside analogs.

摘要翻译： 肝炎病毒感染有效地用错配的dsRNA，特别是rIxr（C11-14，U）n单独或与一种或多种更昔洛韦，香豆霉素A1，双脱氧肌苷或其核苷类似物组合治疗。

公开(公告)号：US4963532A

公开(公告)日：1990-10-16

申请号：US242341

申请日：1988-09-09

申请人： William A. Carter

发明人： William A. Carter

IPC分类号： C07H21/02 ,  A61K31/70 ,  A61K31/80 ,  A61P31/12 ,  A61P43/00 ,  C07H21/00

CPC分类号： A61K31/70 ,  C07H21/00 ,  Y10S514/885 ,  Y10S514/934

摘要： dsRNA reduces the phenomenon of viral escape and cellular damage attendant thereto. Viral escape is a process by which a virus of intracellular pathogen alters its host range or indirectly alters its susceptibility to antiviral or immunological therapies. Viruses do so by causing specific changes in their genomic/antigenic composition and/or by causing the elaboration of factors which enhance destructiveness of cells and their ability to multiply progeny virus. Animals susceptible to viral infections and pathology secondary to antigenic drift may have damage reduced by exposing them to dsRNA which prevents or substantially minimizes viral escape brought about through these mechanisms of molecular rearrangement and/or elaboration of factors which break down the natural host defenses.

公开(公告)号：US4500561A

公开(公告)日：1985-02-19

申请号：US516997

申请日：1983-07-25

申请人： Yong-Wu Kim ,  Phillip L. Coduti ,  Brian A. Sok ,  William A. Carter

发明人： Yong-Wu Kim ,  Phillip L. Coduti ,  Brian A. Sok ,  William A. Carter

IPC分类号： C23C2/26 ,  B05D1/04 ,  B05D1/18

CPC分类号： C23C2/265

摘要： The molten exterior surface portion of a hot dip galvanized steel strip is solidified after the strip is withdrawn from a bath of molten zinc by spraying finely divided particles of a liquid nucleating agent for initiating solidification. The particles are sprayed into an electrostatic field alongside the strip. The particles are initially directed along a path which avoids impingement against the strip. However, the smaller particles are attracted to the strip under the influence of the electrostatic field, to initiate solidification. The larger particles have a momentum along their path large enough to resist the influence of the electrostatic field, thereby permitting the larger particles to continue along a path which avoids impingement. This minimizes the formation of undesirably large spangles and an undesirable surface appearance on the strip.

摘要翻译： 通过喷射细碎的液体成核剂颗粒从熔融锌浴中取出钢带后，将热浸镀锌钢带的熔融外表面部分固化，以引发固化。 颗粒沿着条带被喷射到静电场中。 颗粒最初被引导沿着避免撞击条带的路径。 然而，较小的颗粒在静电场的影响下被吸引到条带上，以引发凝固。 较大的颗粒沿其路径具有足够大的动量以抵抗静电场的影响，从而允许较大的颗粒沿着避免冲击的路径继续。 这使得在条带上形成不期望的大花纹和不期望的表面外观最小化。

公开(公告)号：US4130641A

公开(公告)日：1978-12-19

申请号：US722293

申请日：1976-09-24

申请人： Paul O. P. Ts'o ,  William A. Carter

发明人： Paul O. P. Ts'o ,  William A. Carter

IPC分类号： A61K45/00 ,  C07H21/00 ,  C07H21/02 ,  A61K45/04

CPC分类号： C07H21/00 ,  Y10S435/811 ,  Y10S514/889

摘要： The present invention relates to the induction of interferon production in the cells of living organisms, including human beings. According to the invention, nucleic acid complexes, such as the polyriboinosinate and polycytidylate complex (rI.sub.n .multidot.rC.sub.n), are modified to yield unpaired bases, (uracil or guanine) along the polycytidylate strand which render the complexes more readily hydrolyzable by nucleases present in living cells. The modified complexes retain their ability to stimulate interferon release by the cells but are rendered more vulnerable to destruction within the cells, the modified complexes being significantly less toxic than the original complexes. In addition, polyinosinate strand now has been prepared to contain 5-16% 2'-O-methyl inosinate residues, designated as (rI.sub.5-20, 2'-MeI).sub.n. The new complex (rI.sub.5-20, 2'-MeI).sub.n .multidot.rC.sub.n, exhibits 100-fold more activity than rI.sub.n .multidot.rC.sub.n as an interferon inducer in human cells.

摘要翻译： 本发明涉及包括人在内的生物体细胞中的干扰素产生的诱导。 根据本发明，修饰核酸复合物，例如聚鸟苷酸和聚胞苷酸复合物（rInxrCn），以产生沿着聚胞苷酸链的不成对的碱基（尿嘧啶或鸟嘌呤），其使复合物更容易由存在于活细胞中的核酸酶水解。 修饰的复合物保留其刺激细胞释放干扰素的能力，但更容易受到细胞内的破坏，修饰的复合物的毒性远低于原始复合物。 此外，现在已经制备了聚肌苷酸链，其含有5-16％2'-O-甲基肌氨酸盐残基，命名为（rI5-20,2'-MeI）n。 新的复合物（rI5-20,2'-MeI）nxrCn比人类细胞中干扰素诱导物的rInxrCn活性高出100倍。

公开(公告)号：US20120142537A1

公开(公告)日：2012-06-07

申请号：US13310181

申请日：2011-12-02

申请人： William A. Carter ,  Scott C. Carter ,  Ilkka T. Pylkkanen

发明人： William A. Carter ,  Scott C. Carter ,  Ilkka T. Pylkkanen

IPC分类号： H01P1/00 ,  H01B12/02 ,  H02J3/36

CPC分类号： H01B12/02 ,  H01B12/16 ,  H02G15/34 ,  H02J3/36 ,  H02J2003/365 ,  Y02E40/648 ,  Y02E60/60

摘要： A DC superconducting coaxial transmission system provides electrical transmission of 5,000 megawatts of energy while simultaneously delivering liquid hydrogen. The transmission system includes a coaxial transmission segment including an inner superconductor, an outer superconductor disposed in surrounding relation to the inner conductor, and a dielectric insulator disposed between the inner superconductor and the outer superconductor. Liquid hydrogen surrounds the superconductors. Three phase transformers and poly phase rectifier/inverters provide a DC voltage source to the superconductors from the electrical grid. In one embodiment, a switching circuit connected between the voltage source and the superconductor injects a cancellation current component into the direct current flow. The cancellation current component is polarized to flow in a direction opposite to the direct current flow to produce a current zero, thus enabling safe interruption of the high DC current while minimizing the magnitude of transient voltages during switching.

摘要翻译： DC超导同轴传输系统提供5,000兆瓦能量的电传输，同时输送液态氢。 传动系统包括一个同轴传动段，它包括一个内部超导体，一个围绕内部导体设置的外部超导体，以及设置在内部超导体和外部超导体之间的绝缘绝缘体。 液态氢围绕超导体。 三相变压器和多相整流/逆变器为电网的超导体提供直流电压源。 在一个实施例中，连接在电压源和超导体之间的开关电路将消除电流分量注入到直流电流中。 消除电流分量被极化以在与直流电流相反的方向上流动以产生电流零，从而使得能够在最小化切换期间的瞬态电压的幅度的情况下安全地中断高直流电流。

公开(公告)号：US20090004141A1

公开(公告)日：2009-01-01

申请号：US11713097

申请日：2007-03-02

申请人： William A. Carter ,  David R. Strayer

发明人： William A. Carter ,  David R. Strayer

IPC分类号： A61K38/21 ,  A61P31/12

CPC分类号： A61K38/212

摘要： An antiviral/immunomodulatory response in an animal is induced by oral administration to an infected animal, including humans, of a human α-interferon. Methods of conferring resistance or mitigating the effects of exposure to a virus including avian influenza are described.

摘要翻译： 通过口服给予人α-干扰素的感染动物（包括人）诱导动物中的抗病毒/免疫调节反应。 描述赋予抗性或减轻暴露于禽流感病毒的影响的方法。